CHAIRMAN OF THE BOARD
Tommy G. Thompson:
Tommy G. Thompson was elected as a Director of TherapeuticsMD, Inc. on April 16, 2012. As the former Secretary of the U.S. Department of Health & Human Services Secretary (“HHS”) from February 2001 to January 2005, Secretary Thompson served as the nation’s leading advocate for the health and welfare of all Americans. He worked to modernize and add prescription drug coverage to Medicare for the first time in the program’s history. Secretary Thompson is the former Independent Chairman of the Deloitte Center for Health Solutions and is a former partner of the international law firm of Akin Gump Strauss Hauer & Feld LLP (“Akin Gump”). At the Deloitte Center for Health Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to develop solutions to the health care challenges facing American families, businesses, communities, states and the nation as a whole. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work in expanding healthcare access across all segments of society. Secretary Thompson's experience in public service, in particularly his services and knowledge related to the healthcare industry as a whole, makes him well-suited to be a director of the Company. He received both his B.S. and his J.D. from the University of Wisconsin-Madison. Secretary Thompson also serves as Chairman of CareView Communications, Inc. [OTCQB: CRVW] and serves as a member of the board of directors for C. R. Bard, Inc. [NYSE: BCR], Centene Corporation [NYSE: CNC], United Therapeutics Corporation [NASDAQ: UTHR], and Cytori Therapeutics, Inc. [NASDAQ: CYTX].
16 years of successful, early-stage company development within the healthcare industry. Most notably, Robert co-founded CareFusion (CFN) in 2001, which was sold to Cardinal Health (CAH) in 2006. Robert also gained significant experience as an early employee with Omnicell Technologies (OMCL) and Endoscopy Specialists (TFX) in the healthcare IT and surgical space, respectively. He has a solid track record of successfully building new healthcare companies, while leveraging his background in women’s healthcare, pharmaceutical technology, clinical software, patient safety and distribution. Prior to his healthcare career, Robert was an English teacher at Homachi Bunka in Osaka, Japan and holds a Bachelor of Arts from the University of Miami.
Experienced, entrepreneurial healthcare executive with over 20 years of successful sales, management, business development and operations experience. In 2001, John co-founded clinical technology vendor CareFusion (CFN), which was subsequently sold to Cardinal Health (CAH) in 2006. Previously, John held executive sales and operations management positions with Omnicell Inc. (OMCL), a provider of clinical workflow solutions, Serving Software Inc. and HBOC, the latter two eventually acquired by McKesson (MCK). Throughout his career, John has consistently leveraged his knowledge of the complex healthcare environment to create and accelerate the growth of successful companies. John received his Bachelor of Science degree in Management Engineering from the U.S. Naval Academy.
Dr. Brian Bernick, MD:
Practicing and board-certified Obstetrician/Gynecologist with 20 years of clinical medical experience. Brian is the past Chairman of the Department of Obstetrics and Gynecology at Boca Raton Regional Hospital and has served on their Medical Executive Board. He has also served on the Board of Directors of the Palm Beach Medical Society and VitalMD Group Holding, the largest physician-owned and managed group of obstetricians/gynecologists in Florida. He is the recipient of several national and regional awards, including the American Medical Association Foundation’s Leadership Award. Brian holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the University of Chicago Medical School and completed his residency at the University of Pennsylvania.
Cooper C Collins:
Cooper C. Collins was elected as a Director of TherapeuticsMD, Inc. on February 28, 2012. Mr. Collins was appointed President, Chief Executive Officer and director of Pernix Therapeutics Holdings, Inc. ("Pernix") effective with the close of the merger between Pernix and Golf Trust of America, Inc. on March 9, 2010. Mr. Collins joined Pernix in 2002. He was appointed a director of Pernix in January 2007, Pernix's President in December 2007, and Pernix's Chief Executive Officer in June 2008, serving in those three capacities until the closing of the GTA merger. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix and as Pernix's Territory Manager from December 2003 to December 2005. Over Mr. Collins' tenure as an executive with Pernix, he has been responsible for increasing the overall growth, profitability and efficiency of the organization, overseeing product development and acquisitions, and managing the capital structure of Pernix. Prior to joining Pernix, Mr. Collins was employed for three years by the NFL franchise, The New Orleans Saints, in their media relations department. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
Robert V. LaPenta, Jr. :
Robert V. LaPenta, Jr. was elected as a Director of TherapeuticsMD, Inc. on February 28, 2012. Since August 2011, Mr. LaPenta has served as a Partner of Aston Capital, a private equity investment firm with a current focus on investments in the aerospace, defense, and intelligence markets. Prior to Aston, Mr. LaPenta served as Vice President of Mergers and Acquisitions and Corporate Strategy for L-1 Identity Solutions, Inc., a provider of technology, products, systems and solutions, and services that protect and secure personal identities and assets ("L-1"). From April 2007 through July 2011, Mr. LaPenta assisted L-1 senior management in identifying acquisition candidates and investments while assisting in due diligence, structuring, valuation, execution and related financing. While at L-1, he provided assessment for over 100 acquisition opportunities, assisted in the completion of six public and private transactions, and assisted in the sale of L-1 for $1.7 billion in July 2011.
Prior to L-1, Mr. LaPenta spent thirteen years as an institutional equity trader focused on healthcare sector trading for both customer and proprietary accounts. From February 2003 to March 2007, Mr. LaPenta served as Managing Director, Co-Head of Equity Trading at Banc of America Securities where he managed all capital commitment, proprietary trading and risk management within cash trading. Prior to Banc of America Securities, he served as Director or Vice President of Equity Trading with Credit Suisse First Boston, PaineWebber, Inc., and Salomon Smith Barney, Inc. Previously, as Senior Associate at Coopers & Lybrand, Mr. LaPenta assisted with auditing, consulting, due diligence, and SEC reporting. TherapeuticsMD, Inc. will look to leverage Mr. LaPenta's diverse investing background, capital markets knowledge and his relationships within the financial community to assist it in expanding its market share and investment opportunities.
Mr. LaPenta is Co-Investment Manager of a $250 million family/friends/partners asset portfolio consisting of individual equities, fixed income, equity options, hedge fund strategies, private equity and alternative investments. His responsibilities include asset allocation, stock selection, manager selection and risk management. He has ownership interests in thoroughbred horse racing, breeding and pin hooking. He is an active participant and fund raiser for New York City's W. 63rd Street YMCA, Turn the Corner foundation and numerous other charities. Mr. LaPenta graduated in 1991 from Boston College with a BA in Accounting and Finance and is a registered CPA in the State of New York.
Nicholas Segal was elected as a Director of TherapeuticsMD, Inc. on February 28, 2012. Since June 2007, Mr. Segal has served as a director of Seavest Capital Partners ("Seavest"), a private investment company that invests in early and growth-stage companies primarily in the education, healthcare, consumer technology and media seactors. Representing investments of Seavest, Mr. Segal previously served on the board of VitaMedMD, LLC, prior to its acquisition by TherapeuticsMD, Inc. Mr. Segal serves on the board of directors of TireVan Corporation, a private company specializing in online tire sales and installation directly to the consumer. He also serves as an observer to the board of directors of Tout, a private company with a new social media platform, and Autonet Mobile, a private company specializing in the first Internet-based service platform for the automotive transportation market. Mr. Segal founded and currently serves as Chief Executive Officer of Polar Generation, LLC, an early-stage consumer products company. Mr. Segal has a broad base of knowledge in technologies and products directed to the consumer market. Prior to joining Seavest, from September 2004 to April 2007, Mr. Segal served as a senior analyst in the Finance and Business Development group at ESPN. He graduated with a B.A. from Duke University in 2004.
Jules A. Müsing:
Jules A. Müsing has served as a Director of our company since May 2013. In the course of his 36-year career in the pharmaceutical and biotechnology industry he has been President of Johnson & Johnson companies in the US and in Europe, and was on the Board of Johnson & Johnson companies in Germany, France, Italy and the UK. He has been a member of the Management Board of Ortho Biotech (a J&J Biotechnology Company ) in the US and in Europe.
He was CEO and President of Ares Serono, Inc. in the US and Executive Vice President with responsibilities for Ares Serono companies in North - and Latin America.
In the course of his career at Johnson & Johnson, Jules Müsing has also been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies, and the creation of strategic alliances and partnerships on a global basis.
He established various new scientific, technology and product collaborations in different therapeutic areas, successfully negotiated several licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and was instrumental in the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets.
In this position he signed multiple multi-million dollar deals with small, medium and large pharmaceutical and biotechnology companies worldwide.
Prior to moving into those roles, Jules Müsing was Vice President Marketing International for the Janssen Pharmaceutical Group of Companies Worldwide and was responsible for several business development activities in S.E. Asia where he established Johnson & Johnson subsidiaries in Japan, Australia, South Africa, Thailand and other S.E. Asian countries.
He has been a Board Member of iBio, Inc, and presently serves on the Board of Directors of Delphi Digital, Inc and is Chairman of the Scientific Advisory Board of Noble Capital Financial Markets, a research-driven boutique investment bank focused on emerging growth companies in healthcare, energy, technology, and media & entertainment sectors.
He received his Masters degree in Biological Sciences from the University of Brussels (Belgium) and his Graduate Degree in Economic and Financial Sciences – Magna Cum Lauda – from the University of Antwerp (Belgium).
His work and achievements in the field of Pharmaceutical/Biotechnology Licensing and Business Development has been recognized over the years. As such he received, among others, the prestigious Scrip Award for the Best Partnership Alliance as well as the Recombinant Capital 11th Annual Breakthrough Alliance Award.
He has been speaker at several national and international biotechnology and healthcare conferences and congresses.
J. Martin Carroll:
J. Martin Carroll has served as a director of our company since March 2015. Mr. Carroll previously served as President and Chief Executive Officer of Boehringer Ingelheim Corp. (U.S.) from 2003 until 2011. He also served as global head of strategy and development for Boehringer Ingelheim (Germany) from 2009 through 2012 and served as Chairman of the Board for a number of BI companies. Previously, Mr. Carroll held positions of increasing responsibility with Merck & Co. Inc. from 1976 to 2001, including manufacturing, international (Japan) and marketing and sales. He left Merck serving as its Executive Vice President for Customer Marketing and Sales of the U.S. Human Health Division. From 1972 to 1976, Mr. Carroll served in the United States Air Force. Mr. Carroll has previously served on the board of directors for a number of organizations, including Accredo Health Group Inc., Vivus Inc. [NASDAQ: VVUS], Durata Therapeutics Inc. [NASDAQ: DRTX], and Gwynedd Mercy College, as well as PhRMA. He currently serves as a director of Mallinckrodt PLC [NYSE: MNK]. We believe Mr. Carroll’s extensive experience as a pharmaceutical industry executive and his experience as a director of other publicly traded pharmaceutical companies provides the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. Mr. Carroll received a B.A. in accounting and economics from the College of Holy Cross and a M.B.A. from Babson College.
Angus C. Russell:
Angus C. Russell has served as a director of our company since March 2015. Mr. Russell previously served as Chief Executive Officer of Shire PLC, a biopharmaceutical company, from June 2008 until April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as Executive Vice President of global finance. Prior to joining Shire, Russell served at ICI, Zeneca and AstraZeneca PLC for 19 years, most recently in the role of Vice President, Corporate Finance at AstraZeneca. He is a chartered accountant, having qualified with what is now PriceWaterhouseCoopers LLP. Mr. Russell also serves as a director of Mallinckrodt PLC and BioTime Inc. [NYSE MKT: BTX] and as the chairman of the board of Revance Therapeutics Inc. [NASDAQ: RVNC] Mr. Russell previously served as a director of Shire PLC [NASDAQ: SHPG], Questcor Pharmaceuticals Inc. [NASDAQ: QCOR] and InterMune Inc. [NASDAQ: ITMN]. We believe Mr. Russell’s extensive experience as a pharmaceutical industry executive and his experience as a director of other publicly traded pharmaceutical companies provides the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K.